Skip to main content

Table 1 Baseline characteristics dependent on the height of troponin elevation

From: Postoperative visits by dedicated anesthesiologists in patients with elevated troponin: a retrospective cohort study evaluating postoperative care utility and early detection of complications

 

Overall

TnI

18–119 ng L−1

TnI

120–599 ng L−1

TnI ≥ 600 ng L−1

N

811

543

192

76

Age (median [IQR])

74 [68–80]

74 [68–80]

74 [68–79]

73 [69–79]

Males (%)

505 (62.3)

341 (62.8)

115 (59.9)

49 (64.5)

RCRI score (%)

 0

196 (24.2)

141 (26.0)

45 (23.4)

10 (13.2)

 1

320 (39.5)

215 (39.6)

77 (40.1)

28 (36.8)

 2

191(23.6)

120 (22.1)

45 (23.4)

26 (34.2)

 3 or more

104 (12.8)

67 (12.3)

25 (13.0)

12 (15.8)

High-risk surgery (defined by RCRI) (%)

314 (38.7)

195 (35.9)

82 (42.7)

37 (48.7)

High-risk surgery (defined by ESC/ESA) (%)

124 (15.3)

77 (14.2)

35 (18.2)

12 (15.8)

History of ischemic heart disease (%)

235 (29.0)

145 (26.7)

58 (30.2)

32 (42.1)

History of congestive heart failure (%)

84 (10.4)

60 (11.0)

19 (9.9)

5 (6.6)

History of cerebrovascular disease (%)

201 (24.8)

132 (24.3)

48 (25.0)

21 (27.6)

Insulin dependent diabetes (%)

109 (13.4)

74 (13.6)

24 (12.5)

11 (14.5)

Preoperative creatinine > 2.0 mg dL−1 (%)

113 (13.9)

83 (15.3)

18 (9.4)

12 (15.8)

Arrhythmia (%)

185 (22.8)

136 (25.0)

42 (21.9)

7 (9.2)

ICD or pacemaker (%)

65 (8.0)

53 (9.8)

10 (5.2)

2 (2.6)

Valvular disease (%)

113 (13.9)

82 (15.1)

23 (12.0)

8 (10.5)

Peripheral vascular disease (%)

241 (29.7)

140 (25.8)

66 (34.4)

35 (46.1)

Hypertension (%)

516 (63.6)

347 (63.9)

119 (62.0)

50 (65.8)

Pulmonary disease (%)

210 (25.9)

142 (26.2)

54 (28.1)

14 (18.4)

Active malignancy (%)

255 (31.4)

172 (31.7)

60 (31.2)

23 (30.3)

Renal failure (%)

282 (34.8)

194 (35.7)

58 (30.2)

30 (39.5)

Diabetes mellitus (%)

189 (23.3)

129 (23.8)

41 (21.4)

19 (25.0)

ASA physical status (%)

 1

4 (0.5)

3 (0.6)

0 (0.0)

1 (1.3)

 2

229 (28.2)

161 (29.7)

53 (27.6)

15 (19.7)

 3

481 (59.3)

319 (58.7)

112 (58.3)

50 (65.8)

 4

88 (10.9)

55 (10.1)

25 (13.0)

8 (10.5)

 5

9 (1.1)

5 (0.9)

2 (1.0)

2 (2.6)

METS (%)

 1–3 METS

224 (27.6)

162 (29.8)

42 (21.9)

20 (26.3)

 4–7 METS

373 (46.0)

263 (48.4)

79 (41.1)

31 (40.8)

 8–10 METS

21 (2.6)

10 (1.8)

9 (4.7)

2 (2.6)

 Unknown

193 (23.8)

108 (19.9)

62 (32.3)

23 (30.3)

Emergency surgery (%)

328 (40.4)

213 (39.2)

83 (43.2)

32 (42.1)

Surgical specialty (%)

 General

223 (27.5)

149 (27.4)

58 (30.2)

16 (21.1)

 Gynecological

25 (3.1)

18 (3.3)

5 (2.6)

2 (2.6)

 Head and Neck

78 (9.6)

54 (9.9)

15 (7.8)

9 (11.8)

 Neurological

133 (16.4)

94 (17.3)

28 (14.6)

11 (14.5)

 Orthopedic

104 (12.8)

71 (13.1)

26 (13.5)

7 (9.2)

 Urological

57 (7.0)

42 (7.7)

9 (4.7)

6 (7.9)

 Vascular

191 (23.6)

115 (21.2)

51 (26.6)

25 (32.9)

Locoregional and neuraxial anesthesia (%)

62 (7.6)

45 (8.3)

13 (6.8)

4 (5.3)

  1. Troponin thresholds were chosen based on the thresholds as defined in the local protocol of the University Medical Center Utrecht (TnI 18–119 ng L−1, TnI 120–599 ng L−1, and TnI ≥ 600 ng L−1). Ischemic heart disease was defined as a history of myocardial infarction or previous revascularization, and a history of congestive heart failure was defined as an estimated left ventricular ejection fraction < 40%. Cerebrovascular disease was defined as a history of ischemic stroke, hemorrhagic stroke, or transient ischemic attacks. Renal failure was defined as a glomerular filtration rate (GFR) < 60 ml min−1 in the last 3 months)
  2. ASA American Society of Anesthesiologists classification, ESA European Society of Anaesthesiology, ESC European Society of Cardiology, ICD implantable cardioverter defibrillator, IQR interquartile range, METs metabolic equivalent of task score, RCRI revised cardiac risk index, TnI troponin I